Related Experiment Video
Updated: Jul 15, 2025
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
The Anti-Thrombotic Effects of PCSK9 Inhibitors
Martin Jozef Péč1, Jakub Benko1,2, Jakub Jurica1
1Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia.
Insights
PCSK9 inhibitors effectively lower LDL cholesterol and may also reduce atherosclerosis progression through LDL-independent pathways, impacting platelet activation and inflammation.
Area of Science:
- Cardiovascular medicine
- Molecular biology
- Pharmacology
Background:
- Atherosclerosis, a primary cause of cardiovascular disease, is strongly linked to LDL cholesterol.
- PCSK9 inhibitors are established therapies for lowering LDL cholesterol.
- Emerging evidence suggests PCSK9 inhibitors possess LDL-independent mechanisms against atherosclerosis.
Purpose of the Study:
- To review the impact of PCSK9 inhibitors on atherosclerosis progression.
- To explore the LDL-independent mechanisms of PCSK9 inhibitors.
- To investigate the role of PCSK9 inhibitors in platelet activation, inflammation, endothelial dysfunction, and clot formation.
Main Methods:
- Literature review of studies on PCSK9 inhibitors and atherosclerosis.
- Analysis of molecular mechanisms underlying PCSK9 inhibition.
- Examination of PCSK9's role in platelet activation pathways.
Main Results:
- PCSK9 inhibitors demonstrate efficacy beyond lipid lowering.
- Key effectors of PCSK9-mediated platelet activation include CD36, lipoprotein(a), oxidized LDL, tissue factor, and factor VIII.
- PCSK9 inhibitors influence inflammation and endothelial function.
Conclusions:
- PCSK9 inhibitors offer multifaceted therapeutic benefits in cardiovascular disease.
- Understanding LDL-independent mechanisms is crucial for optimizing PCSK9 inhibitor therapy.
- Further research into novel molecular targets is warranted.
Abstract:
Atherosclerosis is the primary process that underlies cardiovascular disease. The connection between LDL cholesterol and the formation of atherosclerotic plaques is established by solid evidence. PCSK9 inhibitors have proven to be a valuable and practical resource for lowering the LDL cholesterol of many patients in recent years. Their inhibitory effect on atherosclerosis progression seems to be driven not just by lipid metabolism modification but also by LDL-independent mechanisms. We review the effect of PCSK9 inhibitors on various mechanisms involving platelet activation, inflammation, endothelial dysfunction, and the resultant clot formation. The main effectors of PCSK9 activation of platelets are CD36 receptors, lipoprotein(a), oxidised LDL particles, tissue factor, and factor VIII. Many more molecules are under investigation, and this area of research is growing rapidly.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:27Peripheral Artery Disease III: Interprofessional Care